Resul YILMAZ, Şeyda TÜRK, Ruhiye REİSLİ, Sema Tuncer UZUN

A probable case of pregabalin - related reversible hearing loss

Pregabalin and gabapentin are similar compounds with analgesic, anticonvulsant, and anxiolytic characteristics. Due to these pharmacological features, they are commonly used throughout the world in neuropathic pain treatment and anxiety disorders. Mild to moderate side effects of the central nervous system, such as dizziness and somnolence, are important factors in deciding to terminate the use of pregabalin. Studies have also reported that the use of dose-dependent pregabalin resulted in peripheral edema and weight gain. Described in this case report is hearing loss occurring after an increase in the drug dose of a patient using pregabalin.

Pregabaline bağlı gelişen geçici işitme kaybı, beklenmedik bir olgu

Pregabalin ve gabapentin, analjezik, antikonvülsan ve anksiyolitik özelliklere sahip benzer bileşiklerdendir. Bu tür farmakolojik özellikler nedeniyle, nöropatik ağrı tedavisinde ve anksiyete bozukluklarında genel olarak dünyada yaygın olarak kullanılmaktadırlar. Santral sinir sisteminde baş dönmesi ve uyuşukluk gibi hafif ila orta şiddette yan etkiler pregabalinin kullanımını sonlandırmada önemli faktörlerdir. Aynı zamanda, bazı çalışmalarda, doza bağlı pregabalin kullanımı, hastalarda periferik ödem ve kilo vermeye neden olmuştur. Bu olguda, önceden pregabalin kullanan hastanın ilaç dozunda bir artış yapıldıktan sonra oluşan işitme kaybını sunmak istedik.

PDF

___

1. Gilron I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. Curr Opin Anaesthesiol 2007;20(5):456–72.

2. Page RL 2nd, Cantu M, Lindenfeld J, Hergott LJ, Lowes BD. Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. J Cardiovasc Med (Hagerstown) 2008;9(9):922–5.

3. Martinez JA, Kasamatsu M, Rosales-Hernandez A, Hanson LR, Frey WH, Toth CC. Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states. Mol Pain 2012;8:3.

4. Baidya DK, Agarwal A, Khanna P, Arora MK. Pregabalin in acute and chronic pain. J Anaesthesiol Clin Pharmacol 2011;27(3):307–14.

5. Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry 2010;167(7):869.

6. Wood DM, Berry DJ, Glover G, Eastwood J, Dargan PI. Significant pregabalin toxicity managed with supportive care alone. J Med Toxicol 2010;6(4):435–7.

7. Blum A, Simsolo C, Tatour I. Hyponatremia and confusion caused by pregabalin. Isr Med Assoc J 2009;11(11):699– 700.

8. Erdoğan G, Ceyhan D, Güleç S. Possible heart failure associated with pregabalin use: case report. Agri 2011;23(2):80– 3.

9. Sendra JM, Junyent TT, Pellicer MJ. Pregabalin-induced hepatotoxicity. Ann Pharmacother 2011;45(6):e32. 10. Sawant NS, Bokdawala RA. Pregabalin in the treatment of Charles Bonnet syndrome. J Pak Med Assoc 2013;63(4):530–1.

11. Pierce DA, Holt SR, Reeves-Daniel A. A probable case of gabapentin-related reversible hearing loss in a patient with acute renal failure. Clin Ther 2008;30(9):1681–4.

12. Top C, Terekeci H. Gabapentin Kullanımına Bağlı Sensorinöral İşitme Kaybı. Turkiye Klinikleri J Endocrin 2008;3:23–5.

13. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239– 45.

14. Witsell DL, Hannley MT, Stinnet S, Tucci DL. Treatment of tinnitus with gabapentin: a pilot study. Otol Neurotol 2007;28(1):11–5.

15. Bauer CA, Brozoski TJ. Assessing tinnitus and prospective tinnitus therapeutics using a psychophysical animal model. J Assoc Res Otolaryngol 2001;2(1):54–64.

16. Walia KS, Khan EA, Ko DH, Raza SS, Khan YN. Side effects of antiepileptics--a review. Pain Pract 2004;4(3):194–203.

17. Dunner DL. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disord 2005;7(4):307–25.